The Nasdaq-100 has set record highs 55 times over the past 18 months, yet only 764 stocks reached new 52-week highs recently, down from 1,581 a year prior. This disparity raises concerns reminiscent of the late stages before the dot-com bubble burst, when a narrow group of stocks drove gains while the overall market deteriorated.
While the market’s leaders continue to climb, many other stocks are facing losses, indicating potential underlying instability. This phenomenon is further illustrated by Novo Nordisk A/S (NVO), which trades at a lower earnings multiple (14 times earnings) compared to Eli Lilly & Co. (LLY) at 34 times. Despite this, Novo has launched a competitive oral obesity treatment, capturing approximately 76% of the U.S. oral obesity-drug market, presenting a substantial valuation gap worth examining.
Looking ahead, investors are advised to remain cautious as market dynamics shift, especially as the focus between companies developing AI infrastructure versus those leveraging it for profitability begins to reshape investment landscapes around November 4.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
